The expression of GPC3 is significantly up-regulated in peripheral blood of patients with hepatoblastoma, but its sensitivity and specificity is significantly lower than that of AFP, and has nothing to do with prognosis 70; however, GPC3 can be used as an immunohistochemical marker for hepatoblastoma. Here, AFP is linked to hepatoblastoma.